机构：[1]Department of Gynecology, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong 510315, P.R. China.[2]Department of Dermatovenereology, Foshan Maternal and Child Health Hospital, Foshan, Guangdong 528000, P.R. China.[3]Department of Oncology, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong 510315, P.R. China.[4]Department of Gynecology, The First People's Hospital of Huizhou City, Huizhou, Guangdong 516000, P.R. China.[5]Department of Gynecology Oncology, The Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510000, P.R. China.
The aim of the present study was to investigate the expression of myosin 9 (MYH9) in epithelial ovarian cancer and to explore its correlation with the clinicopathological parameters and prognosis of epithelial ovarian cancer (EOC). A total of 265 cases of paraffin-embedded ovarian cancer tissues and 41 paratumor tissues which had been pathologically confirmed at the Memorial Hospital of Sun Yat-sen University from 2009 to 2017 were included in the present study. MYH9 expression was investigated with immunohistochemistry using a polyclonal antibody specific for MYH9. MYH9 expression is associated with disease progression free and overall survival in epithelial ovarian cancer patients; and the expression of MYH9 is associated with International Federation of Gynecology and Obstetrics stage, lymph node metastasis, intraperitoneal metastasis, survival status (at last follow-up), intraperitoneal recurrence, residual tumor size and ascites with tumor cells. Moreover, in a multivariate model MYH9 overexpression was an independent predictor of poor survival in epithelial ovarian cancer. MYH9 may be a candidate that plays a oncogenic role in epithelial ovarian cancer. MYH9 is a useful independent prognostic marker in epithelial ovarian cancer, and it may provide a candidate target therapy treatment of ovarian cancer in the future.
基金：
the Nature Science Fund
of Guangdong Province (grant no. 2016A030313536) and
the Guangdong Provincial Medical Research Fund (grant
no. A2019096).
第一作者机构：[1]Department of Gynecology, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong 510315, P.R. China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Gynecology, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong 510315, P.R. China.[5]Department of Gynecology Oncology, The Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510000, P.R. China.[*1]Department of Gynecology Oncology, The Memorial Hospital of Sun Yat‑sen University, 102 Yanjiang Street, Guangzhou, Guangdong 510000, P.R. China[*2]Department of Gynecology, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, 13 Shiliugang Street, Guangzhou, Guangdong 510315, P.R. China
推荐引用方式(GB/T 7714)：
Liu Longyang,Yi Juanjuan,Deng Xiaojie,et al.MYH9 overexpression correlates with clinicopathological parameters and poor prognosis of epithelial ovarian cancer.[J].ONCOLOGY LETTERS.2019,18(2):1049-1056.doi:10.3892/ol.2019.10406.
APA：
Liu Longyang,Yi Juanjuan,Deng Xiaojie,Yuan Jianhuan,Zhou Beixian...&Zeng Zhaoyang.(2019).MYH9 overexpression correlates with clinicopathological parameters and poor prognosis of epithelial ovarian cancer..ONCOLOGY LETTERS,18,(2)
MLA：
Liu Longyang,et al."MYH9 overexpression correlates with clinicopathological parameters and poor prognosis of epithelial ovarian cancer.".ONCOLOGY LETTERS 18..2(2019):1049-1056
